Judith Trotman
Elite in Waldenstrom Macroglobulinemia

Judith Trotman

Sydney, NSW, AU 
Elite in Waldenstrom Macroglobulinemia
Sydney, NSW, AU 
OverviewLocationsClinical Research

Overview

Judith Trotman practices in Sydney, Australia. Ms. Trotman is rated as an Elite expert by MediFind in the treatment of Waldenstrom Macroglobulinemia. Her top areas of expertise are Follicular Lymphoma, Waldenstrom Macroglobulinemia, Marginal Zone Lymphoma (MZL), Non-Hodgkin Lymphoma, and Bone Marrow Transplant.

Her clinical research consists of co-authoring 154 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 29 articles in the study of Waldenstrom Macroglobulinemia.

Gender
Female

Locations

Sydney, NSW, Australia
Other Locations
Concord, NSW, Australia
Camperdown, NSW, Australia
Camperdown, VIC, Australia
Melbourne, VIC, Australia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

An International, Phase 2, Open-Label, Randomized Study of BGB-3111 Combined With Obinutuzumab Compared With Obinutuzumab Monotherapy in Relapsed/ Refractory Follicular Lymphoma
An International, Phase 2, Open-Label, Randomized Study of BGB-3111 Combined With Obinutuzumab Compared With Obinutuzumab Monotherapy in Relapsed/ Refractory Follicular Lymphoma
Enrollment Status: Completed
Publish Date: January 23, 2025
Intervention Type: Drug
Study Drugs: Zanubrutinib, Obinutuzumab
Study Phase: Phase 2
A Phase 2, Open-label Study of Zanubrutinib (BGB-3111) in Patients With Relapsed or Refractory Marginal Zone Lymphoma
A Phase 2, Open-label Study of Zanubrutinib (BGB-3111) in Patients With Relapsed or Refractory Marginal Zone Lymphoma
Enrollment Status: Completed
Publish Date: October 26, 2024
Intervention Type: Drug
Study Drug: Zanubrutinib
Study Phase: Phase 2
View 1 Less Clinical Trial

154 Total Publications

Expanded CD16+CD56+Granzyme B+ NK like CD8+ T cells an off target effect of bruton's tyrosine kinase inhibitors in Waldenström macroglobulinemia.
Expanded CD16+CD56+Granzyme B+ NK like CD8+ T cells an off target effect of bruton's tyrosine kinase inhibitors in Waldenström macroglobulinemia.
Journal: Scientific reports
Published: February 10, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Trotman's expertise for a condition
ConditionClose
View All 17 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile